Last reviewed · How we verify
Menstrual blood stem cells
At a glance
| Generic name | Menstrual blood stem cells |
|---|---|
| Sponsor | S-Evans Biosciences Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis (PHASE2)
- Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study (PHASE1, PHASE2)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses (PHASE1)
- Menstrual Blood Stem Cells in Poor Ovarian Responders (PHASE3)
- Menstrual Blood Stem Cells in Severe Covid-19 (PHASE1, PHASE2)
- Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection (PHASE1, PHASE2)
- Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure (PHASE1, PHASE2)
- Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Menstrual blood stem cells CI brief — competitive landscape report
- Menstrual blood stem cells updates RSS · CI watch RSS
- S-Evans Biosciences Co., Ltd. portfolio CI